Loading
A phase 2 trial in lung cancer, run by Shanghai Allink Biotherapeutics Co., Ltd., not yet recruiting.
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. is a phase 2, randomised interventional study registered as NCT07742956 by Shanghai Allink Biotherapeutics Co., Ltd., with a registry enrolment figure of 156 participants, started 2026-08-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: ALK201 for injection; Ivonescimab Injection. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: TEAEs. No results are recorded here; the registry entry is the source.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.